SML2293
NSC61610
≥98% (HPLC)
Synonym(s):
CID247228, N1,N4-Bis[3-(1H-benzimidazol-2-yl)phenyl]-1,4-benzenedicarboxamide, NCI 61610
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C34H24N6O2
CAS Number:
Molecular Weight:
548.59
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
color
off-white to purple
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
O=C(C1=CC=C(C=C1)C(NC2=CC=CC(C3=NC4=C(N3)C=CC=C4)=C2)=O)NC5=CC(C6=NC7=C(N6)C=CC=C7)=CC=C5
InChI
1S/C34H24N6O2/c41-33(35-25-9-5-7-23(19-25)31-37-27-11-1-2-12-28(27)38-31)21-15-17-22(18-16-21)34(42)36-26-10-6-8-24(20-26)32-39-29-13-3-4-14-30(29)40-32/h1-20H,(H,35,41)(H,36,42)(H,37,38)(H,39,40)
InChI key
WSXIJTIFOWCMIQ-UHFFFAOYSA-N
Biochem/physiol Actions
NSC61610 is an orally available and potent lanthionine synthetase C-like 2 (LANCL2) ligand that induces IL-10-mediated anti-inflammatory responses that ameliorate disease activity and decrease inflammatory lesions in the gut. Also NSC61610 modulates immune response to influenza A H1N1pdm virus infection in mice.
orally available and potent lanthionine synthetase C-like 2 (LANCL2) ligand
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Andrew Leber et al.
Frontiers in immunology, 8, 178-178 (2017-03-09)
Broad-based, host-targeted therapeutics have the potential to ameliorate viral infections without inducing antiviral resistance. We identified lanthionine synthetase C-like 2 (LANCL2) as a new therapeutic target for immunoinflammatory diseases. To examine the therapeutic efficacy of oral NSC61610 administration on influenza
Adria Carbo et al.
Journal of medicinal chemistry, 59(22), 10113-10126 (2016-12-10)
Lanthionine synthetase C-like 2 (LANCL2), a novel therapeutic target for inflammatory and autoimmune diseases and diabetes, exerts anti-inflammatory and insulin-sensitizing effects. This study reports the first LANCL2-based therapeutics for inflammatory bowel disease (IBD). Analogues of 1 (ABA) and 2 (NSC61610)
Pinyi Lu et al.
PloS one, 7(4), e34643-e34643 (2012-04-18)
Lanthionine synthetase component C-like protein 2 (LANCL2) is a member of the eukaryotic lanthionine synthetase component C-Like protein family involved in signal transduction and insulin sensitization. Recently, LANCL2 is a target for the binding and signaling of abscisic acid (ABA)
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML2293-5MG | 04061835307289 |
| SML2293-25MG | 04061835307272 |